The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gherardi, M. M.
Right arrow Articles by Esteban, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gherardi, M. M.
Right arrow Articles by Esteban, M.
Right arrowPubmed/NCBI databases
*Substance via MeSH
The Journal of Immunology, 2004, 172: 6209-6220.
Copyright © 2004 by The American Association of Immunologists

Induction of HIV Immunity in the Genital Tract After Intranasal Delivery of a MVA Vector: Enhanced Immunogenicity After DNA Prime-Modified Vaccinia Virus Ankara Boost Immunization Schedule 1

M. Magdalena Gherardi, Eva Pérez-Jiménez, José Luis Nájera and Mariano Esteban2

Department of Molecular and Cellular Biology, Centro Nacional de Biotecnologia, Consejo Superior de Investigaciones Científicas, Campus Universidad Autónoma, Madrid, Spain

Vaccines intended to prevent mucosal transmission of HIV should be able to induce multiple immune effectors in the host including Abs and cell-mediated immune responses at mucosal sites. The aim of this study was to characterize and to enhance the immunogenicity of a recombinant modified vaccinia virus Ankara (MVA) expressing HIV-1 Env IIIB Ag (MVAenv) inoculated in BALB/c mice by mucosal routes. Intravaginal inoculation of MVAenv was not immunogenic, whereas intranasally it induced a significant immune response to the HIV Ag. Intranasal codelivery of MVAenv plus cholera toxin (CT) significantly enhanced the cellular and humoral immune response against Env in the spleen and genitorectal draining lymph nodes, respectively. Heterologous DNAenv prime-MVAenv boost by intranasal immunization, together with CT, produced a cellular immune response in the spleen 10-fold superior to that in the absence of CT. A key finding of these studies was that both MVAenv/MVAenv and DNAenv/MVAenv schemes, plus CT, induced a specific mucosal CD8+ T cell response in genital tissue and draining lymph nodes. In addition, both immunizations also generated systemic Abs, and more importantly, mucosal IgA and IgG Abs in vaginal washings. Specific secretion of {beta}-chemokines was also generated by both immunizations, with a stronger response in mice immunized by the DNA-CT/MVA-CT regimen. Our findings are of relevance in the area of vaccine development and support the optimization of protocols of immunization based on MVA as vaccine vectors to induce mucosal immune responses against HIV.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
S. Misumi, M. Masuyama, N. Takamune, D. Nakayama, R. Mitsumata, H. Matsumoto, N. Urata, Y. Takahashi, A. Muneoka, T. Sukamoto, et al.
Targeted Delivery of Immunogen to Primate M Cells with Tetragalloyl Lysine Dendrimer
J. Immunol., May 15, 2009; 182(10): 6061 - 6070.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
V. Revaz, A. Debonneville, M. Bobst, and D. Nardelli-Haefliger
Monitoring of Vaccine-Specific Gamma Interferon Induction in Genital Mucosa of Mice by Real-Time Reverse Transcription-PCR
Clin. Vaccine Immunol., May 1, 2008; 15(5): 757 - 764.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. I. Naslund, C. Uyttenhove, E. K. L. Nordstrom, D. Colau, G. Warnier, M. Jondal, B. J. Van den Eynde, and P. Liljestrom
Comparative Prime-Boost Vaccinations Using Semliki Forest Virus, Adenovirus, and ALVAC Vectors Demonstrate Differences in the Generation of a Protective Central Memory CTL Response against the P815 Tumor
J. Immunol., June 1, 2007; 178(11): 6761 - 6769.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
I. M. Belyakov, D. Isakov, Q. Zhu, A. Dzutsev, D. Klinman, and J. A. Berzofsky
Enhancement of CD8+ T Cell Immunity in the Lung by CpG Oligodeoxynucleotides Increases Protective Efficacy of a Modified Vaccinia Ankara Vaccine against Lethal Poxvirus Infection Even in a CD4-Deficient Host
J. Immunol., November 1, 2006; 177(9): 6336 - 6343.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
Y. Miyahira, Y. Takashima, S. Kobayashi, Y. Matsumoto, T. Takeuchi, M. Ohyanagi-Hara, A. Yoshida, A. Ohwada, H. Akiba, H. Yagita, et al.
Immune Responses against a Single CD8+-T-Cell Epitope Induced by Virus Vector Vaccination Can Successfully Control Trypanosoma cruzi Infection
Infect. Immun., November 1, 2005; 73(11): 7356 - 7365.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
M. M. Gherardi and M. Esteban
Recombinant poxviruses as mucosal vaccine vectors
J. Gen. Virol., November 1, 2005; 86(11): 2925 - 2936.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
M. R. Reynolds, E. Rakasz, P. J. Skinner, C. White, K. Abel, Z.-M. Ma, L. Compton, G. Napoe, N. Wilson, C. J. Miller, et al.
CD8+ T-Lymphocyte Response to Major Immunodominant Epitopes after Vaginal Exposure to Simian Immunodeficiency Virus: Too Late and Too Little
J. Virol., July 15, 2005; 79(14): 9228 - 9235.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2004 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2004 by The American Association of Immunologists, Inc. All rights reserved.